Cullinan Therapeutics Inc. has provided an update on its corporate initiatives, emphasizing the advancement of its clinical-stage programs. The company is progressing with its CLN-978 program, a CD19xCD3 T cell engager, with ongoing enrollment for systemic lupus erythematosus and plans to initiate studies for rheumatoid arthritis and Sjögren's disease. Additionally, Cullinan is advancing its oncology pipeline, including the anticipated pivotal study results for zipalertinib, shared at ASCO 2025, with a potential NDA submission later in the year. The company maintains a robust financial position, with a cash runway extending into 2028. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.